$CRBP

Saxena Nishant C (Chief Business Officer) purchased 2,600 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $9.63 on 2026-08-11.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 crbp-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “ Agreement ”), dated as of August 03, 2026 (the “ Effective Date ”), is entered into by and between Corbus Pharmaceuticals Holdings, Inc. (the “ Company ”) and Leonardo Vi

Saxena Nishant C (Chief Business Officer) purchased 9,000 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $7.58 on 2026-06-03.

Saxena Nishant C (Chief Business Officer) purchased 4,500 shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) at $7.33 on 2026-06-02.

Corbus Pharmaceuticals (CRBP) reported updated Phase 1/2 data for CRB-701 in 2L oropharyngeal and cervical cancers, based on an April 1, 2026 cut with 317 patients. It cited ORR of 42.9% (median DOR 6.3 months, PFS 5.6) in OPSCC and 34.4% (DOR 8.0, PFS 4.3) in cervical cancer. The company plans registrational trials starting with TEMPO-1 in summer 2026; shares were down 12.79% pre-market to $9.90.

Oppenheimer has revised its price target for Corbus Pharmaceuticals (NASDAQ: CRBP) to $54, down from the previous $57, while reiterating an Outperform rating. The article, primarily a headline and a company overview, also lists several recent news items related to Corbus Pharmaceuticals from April and March 2026, including other analyst rating adjustments and clinical trial updates.

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported a wider Q1 2026 net loss of $22.97 million, up from $16.98 million a year earlier, primarily due to increased research and development expenses for its oncology and obesity pipeline programs. Despite the loss, the company ended the quarter with $138.2 million in cash, cash equivalents, and investments, which it anticipates will fund operations for at least 12 months. Corbus is advancing CRB-701 for oncology and CRB-913 for obesity, with a new $300 million shelf registration and remaining at-the-market equity program capacity to support future funding needs.

Corbus Pharmaceuticals recently updated the employment agreements for CEO Yuval Cohen and CFO Sean Moran, extending their terms until April 2028. These amendments enhance severance, equity, and change-of-control protections, aiming to ensure leadership stability and align executive interests with shareholders. While the company faces financial challenges, a recent analyst rating suggests a Buy for CRBP stock, with Spark's AI Analyst giving a Neutral score.

Corbus Pharmaceuticals reported a wider net loss of $78.5 million in 2025 due to increased R&D spending, but significantly strengthened its cash position to $163.3 million, expected to fund operations into 2028. The company highlighted promising clinical data for its oncology candidate CRB-701 in head and neck, cervical, and bladder cancers, and for its obesity drug CRB-913, which showed early weight loss with a favorable safety profile. Key data readouts for both programs are anticipated in mid-2026, positioning 2026 as a potentially transformative year for Corbus.